Stockscreener 앱 받기
0.75%
시간 외 거래:
전일 마감가:
$331.49
열려 있는:
$330.72
하루 거래량:
833.67K
Relative Volume:
0.31
시가총액:
$179.83B
수익:
$35.89B
순이익/손실:
$7.01B
주가수익비율:
25.82
EPS:
12.9352
순현금흐름:
$11.54B
1주 성능:
+2.44%
1개월 성능:
-0.10%
6개월 성능:
+20.35%
1년 성능:
+26.27%
1일 변동 폭
$330.72
$334.38
1주일 범위
$321.91
$334.38
52주 변동 폭
$257.05
$346.38
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
AMGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
333.96 | 178.50B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,076.98 | 959.14B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.78 | 495.78B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.89 | 404.36B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
138.88 | 266.96B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
106.45 | 260.71B | 63.90B | 19.05B | 13.05B | 7.5596 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Brookstone Capital Management Acquires 16,042 Shares of Amgen Inc. $AMGN - MarketBeat
Farther Finance Advisors LLC Buys 3,158 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know - The Globe and Mail
Swedbank AB Sells 283,479 Shares of Amgen Inc. $AMGN - MarketBeat
Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 73% Return On Equity? - Yahoo Finance
Amgen Inc. $AMGN Shares Bought by Global X Japan Co. Ltd. - MarketBeat
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice? - The Globe and Mail
Revolve Wealth Partners LLC Sells 12,066 Shares of Amgen Inc. $AMGN - MarketBeat
Exchange Traded Concepts LLC Has $17.78 Million Position in Amgen Inc. $AMGN - MarketBeat
Is There Still Value in Amgen After Its Strong 2025 Share Price Run? - simplywall.st
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know - sharewise.com
Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open - ts2.tech
Fitch upgrades Amgen to ’BBB+’ on improved financial structure By Investing.com - Investing.com Nigeria
Fitch upgrades Amgen to ’BBB+’ on improved financial structure - Investing.com
Fitch raises Amgen credit rating, outlook stable - breakingthenews.net
Our Workforce - Amgen
Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025 - ts2.tech
Amgen’s Pediatric Inebilizumab Study Signals Long-Term Upside in Rare Autoimmune Disease - TipRanks
Matrix Asset Advisors Inc. NY Purchases 4,633 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc (NASDAQ:AMGN) Nasdaq Index Biotechnology Leadership Focus - Kalkine Media
Amgen Inc. (NASDAQ:AMGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amgen (AMGN) price target trimmed at Morgan Stanley as policy risks ease - MSN
Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025) - ts2.tech
Assessing Amgen (AMGN) Valuation After UPLIZNA Approval and New U.S. Drug Pricing Agreements - simplywall.st
The Best Dividend ETF to Buy: SCHD Pays a High Yield While VIG Focuses on Dividend Growth - The Motley Fool
Sarasin & Partners LLP Buys 47,873 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Foster Victor Wealth Advisors LLC - MarketBeat
Signal Advisors Wealth LLC Has $867,000 Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by CHICAGO TRUST Co NA - MarketBeat
Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts - ts2.tech
Voya Investment Management LLC Sells 275,398 Shares of Amgen Inc. $AMGN - MarketBeat
Bartlett & CO. Wealth Management LLC Reduces Stock Position in Amgen Inc. $AMGN - MarketBeat
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal - Benzinga
Has Amgen’s 26% Rally in 2025 Already Priced In Its Obesity and Oncology Ambitions? - Yahoo Finance
Is Amgen Inc. stock a top momentum playWeekly Stock Summary & Daily Stock Trend Watchlist - ulpravda.ru
Amgen to Cut US Drug Prices, Expand Patient Access - marketscreener.com
Amgen takes action with U.S. government to lower medicine costs By Investing.com - ca.investing.com
Amgen says Aimovig & Amjevita to be available at discounted monthly price of $299 under deal with U.S. govt - marketscreener.com
Amgen (AMGN) Moves to Reduce Drug Prices in Collaboration with U - GuruFocus
Amgen Strikes Agreement With US Government to Lower Drug Costs - marketscreener.com
AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS - PR Newswire
Amgen Advances Olpasiran Heart Plaque Study, Highlighting a Growing Bet on Lipoprotein(a) - TipRanks
Talbot Financial LLC Purchases 5,839 Shares of Amgen Inc. $AMGN - MarketBeat
Bristol Myers, Merck, Amgen among latest to announce U.S. drug pricing deal - Seeking Alpha
Is Amgen Inc. stock trading near support levels2025 Price Momentum & Technical Confirmation Trade Alerts - DonanımHaber
How Amgen Inc. stock reacts to oil pricesJuly 2025 Review & Community Trade Idea Sharing Platform - DonanımHaber
How Amgen Inc. stock performs in weak economy2025 Analyst Calls & Weekly Top Performers Watchlists - Улправда
Chemotherapy Induced Anemia Market Intelligence Report 2025-2032, Featuring Amgen, Johnson & Johnson - PharmiWeb.com
Why Amgen Inc. stock remains on watchlistsJuly 2025 Spike Watch & Free Fast Gain Swing Trade Alerts - Улправда
Czech National Bank Has $38.59 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Inductive Bio, Amgen Join ARPA-H’s Push To Replace Animal Tox With AI And Human Tissues - Citeline News & Insights
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
암젠 주식 (AMGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
0.38%
자본화:
|
볼륨(24시간):